QuidelOrthoQDEL
Recorded

QuidelOrtho 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration36 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the QuidelOrtho third quarter 2026 financial results conference call and webcast. At this time, all participants' lines are in a listen-only mode. For those of you participating in the conference call, there will be an opportunity for your questions at the end of today's prepared remarks. Please note, this conference call is being recorded. An audio replay of the conference call will be available on the company's website shortly after this call. I would now like to turn the call over to Sanjeev Sharma, Vice President of Investor Relations.

Sanjeev SharmaVP of Investor Relations

Sanjeev, please go ahead. Good afternoon, everyone, and thank you for joining us on our earnings call.

Sanjeev SharmaVP of Investor Relations

With us today, we have Brian Blaser, our President and Chief Executive Officer, and Micah Young, our Chief Financial Officer. This conference call is being simultaneously webcast on the IR section of our website. To assist in the presentation, we also posted supplemental information on the Investor Relations page that will be referenced throughout this call. Please note that this conference call and supplemental information contain forward-looking statements, including the company's expectations, plans, financial guidance, and various strategic initiatives. We assume no obligation to update any forward-looking statement, except as required by law. These statements are made as of today and are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in these statements. Please refer to our SEC filings for a description of potential risks.

Sanjeev SharmaVP of Investor Relations

In addition, today's call includes discussion of certain non-GAAP financial measures. Tables reconciling these non-GAAP measures to their most directly comparable GAAP measures are available in our earnings release and supplemental information on the Investor Relations page of our website. Lastly, unless stated otherwise, all year-over-year revenue growth rates given on today's call are on a constant currency basis. With that, I would like to turn the call over to our President and CEO, Brian Blaser.

Brian BlaserPresident and CEO

Thanks, Sanjeev, and good afternoon, everyone. I would like to begin with three important takeaways from the quarter. First, the underlying performance of our business remains resilient. Labs and immunohematology, which represent 70%-75% of our revenue, excluding China, delivered low to mid-single-digit organic growth. Second, our reported results continue to reflect two significant near-term headwinds: the impact of China's now finalized nationwide IVD pricing guidelines and the softer respiratory testing environment in Point of Care. Third, we are acting decisively and launching a new cost transformation and enterprise restructuring program designed to improve profitability and cash generation while evolving our operating model around the distinct needs of our customers and markets. These actions are intended to strengthen execution today and position QuidelOrtho for sustainable, profitable growth over the long term. Turning to our third quarter results, total reported revenue was $619 million, down 12% from last year.

Brian BlaserPresident and CEO

Revenue increased 3%, excluding China, respiratory, and the prior year contribution from the U.S. Donor Screening business, which we are winding down. Labs revenue outside China grew 4%, supported by the strength and durability of our customer relationships and large global installed base. Immunohematology revenue outside China increased 3%, reflecting steady demand across key markets and our strong position in the segment. Together, these results reinforce an important point. The underlying fundamentals of our business remain healthy. We serve large and attractive diagnostic markets, hold leading positions across multiple categories, and benefit from recurring revenue streams supported by long-term customer relationships and a substantial installed base. Point of Care revenue declined 27% year over year, including a 39% decline in respiratory revenue. As anticipated, respiratory demand remained below the prior year period.

Brian BlaserPresident and CEO

Given the inherent variability of respiratory trends, our outlook continues to reflect cautious assumptions for the balance of the year based on activity through the end of the third quarter. China revenue declined 45% year over year as distributors and customers continued to reduce purchasing and inventory levels related to the nationwide IVD pricing guidelines, which were finalized in mid-August. Implementation of the guidelines is expected to begin in six provinces by the end of this year, with timing determined at the provincial level. The final guidelines were generally consistent with the second draft released in June and broadly removed pricing differentiation by methodology. Provincial implementation timing remains uncertain. Based on what we know today, we expect continued destocking throughout the remainder of 2026 and increased pricing pressure in 2027 as pricing changes are implemented throughout next year. We are managing this transition with urgency and discipline.

Brian BlaserPresident and CEO

We are working closely with our China team, customers, and distribution partners to adapt our commercial model as the market evolves. Our priorities are clear: support customers, protect the installed base, align costs with expected business activity, and preserve the long-term value of our China franchise. Today, we also announced a new cost transformation and enterprise restructuring program to position QuidelOrtho for sustainable long-term profitable growth. We are improving our cost structure and reshaping the organization around our customers, their needs, and the economics of the business. Enterprise optimization and restructuring are the immediate parts of that work. The objective is not simply to reduce costs. It is to strengthen underlying performance. As part of this program, we are evolving our operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics.

Brian BlaserPresident and CEO

The Point of Care Diagnostics business will include our Sofia, Triage, and NULEXA product lines aligned with near-patient testing performed primarily in clinics, physicians' offices, and emergency rooms. Core Diagnostics will bring together our Labs, Immunohematology, and informatics portfolios, serving the needs of clinical laboratories, hospitals, and blood banks. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. We expect this program to deliver over $80 million in annual savings in 2027. These actions are intended not only to mitigate near-term China headwinds next year, but also to structurally improve QuidelOrtho's earnings profile and cash generation. Our priorities remain consistent: expand profitability, improve free cash flow, and reduce leverage. Micah will provide additional details shortly.

Brian BlaserPresident and CEO

As we execute our cost and restructuring program, we plan to protect targeted investments in innovation and growth platforms where we see clear customer value, differentiated capability, and attractive returns. We remain committed to making these focused investments to enable the next phase of QuidelOrtho's growth. For example, within our Labs business, we are expanding the VITROS 450 launch to additional key international markets, empowering low-volume and community-based labs with our next-generation analyzer designed to deliver differentiated dry slide performance with high-quality and consistent results at lower costs. NULEXA, our Point of Care molecular platform, is another example of our focused approach. Since closing the acquisition of LEX earlier this year, we have made meaningful progress building manufacturing and commercial launch capabilities. NULEXA remains in the early stages of launch, and we are balancing investment with disciplined cost management.

Brian BlaserPresident and CEO

Early customer engagement supports our view that its combination of molecular-level performance, speed, and workflow simplicity addresses an important unmet need in the Point of Care market. Beyond the initial respiratory menu, NULEXA provides a scalable platform with meaningful menu expansion opportunities. Combined with our broad commercial reach and deep customer relationships in Point of Care diagnostics, we believe NULEXA can become an important contributor to our long-term growth strategy. As we enter respiratory season, our focus is on building placements, driving utilization, and expanding the installed base ahead of the 2027-2028 season. With that, I'll turn the call over to Micah.

Micah YoungCFO

Micah? Thank you, Brian, and good afternoon, everyone.

Micah YoungCFO

Before reviewing our third quarter financial results, I want to provide additional perspective on the cost transformation and enterprise restructuring program announced today and how we expect it to strengthen our earnings profile, cash generation, and financial position over time. Last quarter, I outlined three immediate priorities as CFO: strengthen operating discipline, improve cash conversion, and reduce leverage. Since then, we've conducted a detailed review of the operating model, cost structure, and portfolio to identify where we can simplify the organization, align resources with current market realities, and preserve funding for the highest return growth opportunities. Consistent with those priorities, the program announced today is expected to deliver more than $80 million of annual savings in 2027.

Micah YoungCFO

These actions are designed to align resources with the distinct needs of our customers and markets, strengthen financial discipline, and improve the rigor of our investment decisions. We expect to record approximately $30 million-$35 million of one-time restructuring charges in the fourth quarter, with the majority of the related cash outflow occurring in the fourth quarter of 2026. Together, these actions are intended to create a more efficient cost structure that can absorb near-term headwinds, improve earnings and cash conversion, and support sustainable profitable growth. Let me now review our third quarter results. Total reported revenue was $619 million, representing a 12% year-over-year decline on a constant currency basis. As expected, the quarter was affected by continued pressures in China related to changes in the nationwide IVD pricing guidelines and by a softer respiratory environment. Excluding China, respiratory, and the Donor Screening wind-down, revenue increased 3%.

Micah YoungCFO

Labs and immunohematology represented 73% of total company revenue, excluding China, and grew at a low to mid-single-digit rate. Outside China, Labs grew 4% and immunohematology grew 3% on a constant currency basis. Growth was broad-based across several key geographies, including Latin America, Japan, and Asia Pacific. China revenue declined 45% year-over-year as customers reduced purchasing and inventory levels in response to the nationwide IVD pricing guidelines. While provincial implementation schedules remain uncertain, we expect continued customer caution and destocking for the remainder of 2026, with the majority of the pricing impact expected in 2027. Based on our current assessment, we expect China to represent approximately 8% of total company revenue in 2026 and approximately 4%-5% in 2027. Turning to profitability, adjusted gross margin was 47.8%, down 90 basis points year-over-year, primarily reflecting lower revenue and unfavorable product mix, partially offset by cost actions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day